Angela Dispenzieri Selected Research

Lenalidomide (CC 5013)

1/2022	A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
1/2021	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
1/2021	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM).
1/2021	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma.
1/2021	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy.
12/2020	Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
11/2020	Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
11/2018	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.
1/2018	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.
11/2017	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Angela Dispenzieri Research Topics

Disease

166	Multiple Myeloma 12/2022 - 11/2002
135	Immunoglobulin Light-chain Amyloidosis 01/2022 - 03/2002
123	Amyloidosis 11/2022 - 01/2002
32	Paraproteinemias (Monoclonal Gammopathy) 01/2022 - 01/2002
27	POEMS Syndrome (Syndrome, POEMS) 12/2022 - 04/2003
23	Neoplasms (Cancer) 01/2022 - 01/2005
18	Monoclonal Gammopathy of Undetermined Significance 01/2022 - 07/2004
17	Plasmacytoma 01/2021 - 06/2004
16	Amyloid Plaque 09/2022 - 01/2002
16	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2021 - 01/2002
15	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 01/2005
14	Disease Progression 04/2022 - 07/2004
13	Proteinuria 01/2022 - 01/2005
13	Cardiomyopathies (Cardiomyopathy) 11/2021 - 01/2002
12	Polyradiculoneuropathy (Polyradiculoneuritis) 01/2021 - 07/2011
11	Castleman Disease (Castleman's Disease) 01/2022 - 07/2011
9	Transthyretin-Related Hereditary Amyloidosis 09/2022 - 07/2014
9	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 02/2005
9	Smoldering Multiple Myeloma 01/2021 - 07/2004
9	Anemia 11/2020 - 01/2003
8	Heart Failure 11/2021 - 04/2014
7	Lymphoma (Lymphomas) 01/2021 - 03/2011
6	Thrombocytosis (Thrombocythemia) 01/2022 - 05/2008
6	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 07/2004
6	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 01/2018 - 01/2005
5	Polyneuropathies (Polyneuropathy) 01/2021 - 05/2015
5	Thrombocytopenia (Thrombopenia) 01/2020 - 04/2006
5	Hypercalcemia (Milk Alkali Syndrome) 01/2020 - 01/2003
5	Renal Insufficiency (Renal Failure) 12/2019 - 06/2010
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 03/2003
5	Familial Amyloidosis (Hereditary Amyloidosis) 01/2018 - 07/2014
4	Hypoalbuminemia 01/2022 - 01/2005
4	Pleural Effusion (Pleural Effusions) 01/2021 - 06/2010
4	Rare Diseases (Rare Disease) 01/2021 - 01/2008
4	Trisomy (Trisomies) 12/2020 - 09/2005
4	Cardiac Arrhythmias (Arrythmia) 12/2019 - 06/2010
4	Infections 10/2018 - 11/2002
4	Acute Kidney Injury (Acute Renal Failure) 06/2018 - 01/2005
4	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2018 - 09/2006
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 09/2005
3	Pulmonary Hypertension 01/2021 - 01/2015

Drug/Important Bio-Agent (IBA)

69	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2002
62	Amyloid (Amyloid Fibrils)IBA 09/2022 - 03/2003
43	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 01/2021 - 07/2005
39	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 01/2002
36	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 11/2005
28	Lenalidomide (CC 5013)FDA Link 01/2022 - 10/2006
28	Immunoglobulin M (IgM)IBA 01/2021 - 01/2002
27	Bortezomib (Velcade)FDA Link 01/2022 - 07/2005
21	Prealbumin (Transthyretin)IBA 09/2022 - 12/2013
21	Thalidomide (Thalomid)FDA Link 01/2022 - 11/2002
16	Biomarkers (Surrogate Marker)IBA 05/2021 - 06/2010
15	Melphalan (Alkeran)FDA LinkGeneric 12/2021 - 01/2002
14	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 03/2006
13	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 05/2008
10	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2019 - 09/2004
9	Troponin T (Troponin T1)IBA 01/2021 - 05/2007
8	Immunoglobulin G (IgG)IBA 01/2022 - 06/2010
8	Congo RedIBA 01/2022 - 04/2013
8	Proteasome InhibitorsIBA 01/2022 - 05/2006
8	pro-brain natriuretic peptide (1-76)IBA 01/2021 - 10/2010
8	CreatinineIBA 12/2020 - 01/2002
6	ixazomibIBA 01/2022 - 11/2016
6	Immunomodulating AgentsIBA 01/2022 - 10/2009
6	Pharmaceutical PreparationsIBA 01/2022 - 10/2010
6	pomalidomideIBA 03/2021 - 10/2009
6	Immunoglobulin A (IgA)IBA 01/2021 - 06/2010
6	Interleukin-6 (Interleukin 6)IBA 12/2020 - 02/2006
6	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2019 - 10/2003
5	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 10/2003
5	Biological ProductsIBA 10/2021 - 02/2006
5	Serum AlbuminIBA 01/2021 - 11/2005
5	TroponinIBA 10/2019 - 05/2003
5	Peptides (Polypeptides)IBA 02/2017 - 04/2014
4	patisiranIBA 01/2021 - 01/2019
4	AlbuminsIBA 12/2020 - 05/2007
4	VaccinesIBA 12/2020 - 12/2009
4	Radioisotopes (Radionuclides)IBA 01/2020 - 01/2002
4	daratumumabIBA 01/2020 - 11/2017
4	Rituximab (Mabthera)FDA Link 08/2018 - 09/2006
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2018 - 03/2007
4	Blood Proteins (Serum Proteins)IBA 10/2016 - 12/2011
4	Indicators and Reagents (Reagents)IBA 10/2015 - 02/2003
4	thiamine triphosphorate (TTP)IBA 06/2015 - 04/2003
4	Alkylating AgentsIBA 05/2012 - 03/2003
3	Hemoglobins (Hemoglobin)IBA 01/2022 - 01/2018
3	sodium-iodide symporter (sodium iodide symporter)IBA 01/2022 - 10/2017
3	AntibodiesIBA 01/2021 - 09/2006

Therapy/Procedure

146	Therapeutics 11/2022 - 01/2002
82	Stem Cell Transplantation 11/2022 - 11/2002
27	Drug Therapy (Chemotherapy) 01/2021 - 11/2002
16	Transplantation 10/2022 - 03/2003
13	Hematopoietic Stem Cell Transplantation 03/2021 - 03/2004
12	Kidney Transplantation 04/2022 - 07/2005
11	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 01/2015 - 01/2002
9	Autologous Transplantation 01/2017 - 12/2009
8	Cell Transplantation 12/2022 - 08/2011
4	Lasers (Laser) 10/2019 - 12/2010
4	Radiotherapy 08/2017 - 07/2005
3	Hematopoietic Stem Cell Mobilization 01/2021 - 11/2005